Top

Published in:

01-04-2023 | Diazepam | Current Perspectives

Seizure Rescue Therapies: Comparing Approved and Commonly Used Benzodiazepine Formulations

Authors: Gregory L. Krauss, Reena Elizebath, Naluca Mwendaweli

Published in: Neurotherapeutics | Issue 3/2023

Abstract

Acute seizure therapies given out of the hospital are important for interrupting acute repetitive and prolonged seizures and preventing hospitalization. These vary in their administration routes, indications for children and adults, pharmacologic profiles, and efficacy. We reviewed and compared the uses of current formulations available to treat acute seizures, including newly released intranasal (IN) benzodiazepines and older formulations which are widely used for interrupting seizures.

Wolf P. Acute administration of benzodiazepines as part of treatment strategies for epilepsy. CNS Neurosci Ther. 2011;17:214–20.CrossRefPubMed

Wallace A, Wirrell E, Payne E. Seizure rescue medication use among US pediatric epilepsy providers: a survey of the pediatric epilepsy research consortium. J Pediatr. 2019;212:111–6.CrossRefPubMed

Haut SR, Nabbout R. Recognizing seizure clusters in the community: the path to uniformity and individualization in nomenclature and definition. Epilepsia. 2022;63:S6–13.CrossRefPubMed

Jafarpour S, Hirsch LJ, Gaínza-Lein M, Kellinghaus C, Detyniecki K. Seizure cluster: definition, prevalence, consequences, and management. Seizure. 2019;68:9–15.CrossRefPubMed

Detyniecki K, O’Bryan J, Choezom T, Rak G, Ma C, Zhang S, et al. Prevalence and predictors of seizure clusters: a prospective observational study of adult patients with epilepsy. Epilepsy Behav. 2018;88:349–56.CrossRefPubMed

Mesraoua B, Abou-Khalil B, Hosni Khodair R, Melikyan G, Al Hail H, Asadi-Pooya AA. Seizure clusters J Drug Assess. 2021;10:86–90.CrossRefPubMed

McIntyre J, Robertson S, Norris E, Appleton R, Whitehouse WP, Phillips B, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. The Lancet. 2005;366:205–10.CrossRef

Scott RC. Buccal midazolam as rescue therapy for acute seizures. The Lancet Neurol. 2005;4:592–3.CrossRefPubMed

Clonazepam orally disintegrating tablets product insert. Available at: https://www.parpharm.com/pdfs/catalog/generic/Clonazepam_ODT_PI_20220420.pdf. Accessed 10 Nov 2022.

10.

Troester MM, Hastriter EV, Ng Y. Dissolving oral clonazepam wafers in the acute treatment of prolonged seizures. J Child Neurol. 2010;25:1468–72.CrossRefPubMed

11.

Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345:631–7.CrossRefPubMed

12.

Kwok C, Gutierrez EG, Krauss G. Acute treatment of prolonged and repetitive seizures in adults using sublingual administration of lorazepam intensol 2 mg/ml solution (P1.265). Neurology 2018;90:P1.265. Abstract.

13.

Gastaut H, Naquet R, Poiré R, Tassinari CA. Treatment of status epilepticus with diazepam (Valium). Epilepsia. 1965;6:167–82.CrossRefPubMed

14.

Henriksen PB. Acute treatment of epileptic seizures with diazepamum (Valium). Acta Neurol Scand. 1967;43:168–9.CrossRefPubMed

15.

Dreifuss FE, Rosman NP, Cloyd JC, Pellock JM, Kuzniecky RI, Lo WD, et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med. 1998;338:1869–75.CrossRefPubMed

16.

Cereghino JJ, Mitchell WG, Murphy J, Kriel RL, Rosenfeld WE, Trevathan E. Treating repetitive seizures with a rectal diazepam formulation: a randomized study. The North American Diastat Study Group. Neurology 1998;51:1274–1282.

17.

Diastat (diazepam rectal gel) Product Insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020648s014lbl.pdf. Accessed 10 Nov 2022.

18.

Tatum WO IV. Adult patient perceptions of emergency rectal medications for refractory seizures. Epilepsy Behav. 2002;3:535–8.CrossRef

19.

Penovich P, Wheless JW, Hogan RE, Guerra C, Cook DF, Carrazana E, et al. Examining the patient and caregiver experience with diazepam nasal spray for seizure clusters: results from an exit survey of a phase 3, open-label, repeat-dose safety study. Epilepsy Behav. 2021;121:1–7.CrossRef

20.

Henney HR, Sperling MR, Rabinowicz AL, Bream G, Carrazana EJ. Assessment of pharmacokinetics and tolerability of intranasal diazepam relative to rectal gel in healthy adults. Epilepsy Res. 2014;108:1204–11.CrossRefPubMed

21.

Hogan RE, Tarquinio D, Sperling MR, Klein P, Miller I, Segal EB, et al. Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal/peri-ictal) and nonseizure (interictal) conditions: a phase 1, open-label study. Epilepsia. 2020;61:935–43.CrossRefPubMedPubMedCentral

22.

Center for Drug Evaluation and Research. Clinical pharmacology review of Valtoco. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211635Orig1s000ClinPharmR.pdf. Accessed 11 Nov 2022.

23.

Center for Drug Evaluation and Research. Clinical review of Valtoco. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211635Orig1s000MedR.pdf. Accessed 11 Nov 2022.

24.

Wheless JW, Miller I, Hogan RE, Dlugos D, Biton V, Cascino GD, et al. Final results from a phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy. Epilepsia. 2021;62:2485–95.CrossRefPubMedPubMedCentral

25.

Sperling MR, Wheless JW, Hogan RE, et al. Use of second doses of Valtoco® (diazepam nasal spray) across 24 hours after the initial dose for out-of-hospital seizure clusters: Results from a phase 3, open-label, repeat-dose safety study. Epilepsia. 2022;63(4):836–43. https://doi.org/10.1111/epi.17177.CrossRefPubMedPubMedCentral

26.

Cascino GD, Tarquinio D, Wheless JW, et al. Lack of observed tolerance to diazepam nasal spray (Valtoco®) after long-term rescue therapy in patients with epilepsy: interim results from a phase 3, open-label, repeat-dose safety study. Epilepsy Behav. 2021;120:107983. https://doi.org/10.1016/j.yebeh.2021.107983.

27.

Tarquinio D, Dlugos D, Wheless JW, Desai J, Carrazana E, Rabinowicz AL. Safety of diazepam nasal spray in children and adolescents with epilepsy: results from a long-term phase 3 safety study. Pediatr Neurol. 2022;132:50–5.CrossRefPubMed

28.

Rogawski MA, Slatko G. A randomized, open-label, two-treatment crossover study to evaluate the effect of food on the pharmacokinetics of diazepam nasal spray in healthy adults. Epilepsia. 2023;64(2):364–73. https://doi.org/10.1111/epi.17459.CrossRefPubMed

29.

Intranasal diazepam (Valtoco) and midazolam (Nayzilam) for seizure clusters. Med Lett Drugs Ther 2020;62:63–64.

30.

Diazepam Oral Solution [package insert]. Columbus, OH: Roxane Laboratories, Inc.; 2012. Available at: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Roxane/Diazepam/Diazepam%20Oral%20Solution.pdf. Accessed 10 Nov 2022.

31.

Schwagmeier R, Alincic S, Striebel HW. Midazolam pharmacokinetics following intravenous and buccal administration. Br J Clin Pharmacol. 1998;46:203–6.CrossRefPubMedPubMedCentral

32.

Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet. 1999;353:623–6.CrossRefPubMed

33.

Bhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatr Neurol. 2006;34:355–9.CrossRefPubMed

34.

Midazolam Intramuscular Autoinjector Product Insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216359s000lbl.pdf. Accessed 30 Jan 2023.

35.

Silbergleit R, Lowenstein D, Durkalski V, Conwit R. The Neurological Emergency Treatment Trials (NETT) Investigators. RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. Epilepsia. 2011;52:45–47.

36.

De Haan G, Van Der Geest P, Doelman G, Bertram E, Edelbroek P. A comparison of midazolam nasal spray and diazepam rectal solution for the residential treatment of seizure exacerbations. Epilepsia. 2010;51:478–82.CrossRefPubMed

37.

Center for Drug Evaluation and Research. Clinical review of Nayzilam. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211635Orig1s000ClinPharmR.pdf. Accessed 11 Nov 2022.

38.

Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review of Nayzilam. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211321Orig1s000ClinPharmR.pdf. Accessed 11 Nov 2022.

39.

Detyniecki K, Van Ess PJ, Sequeira DJ, Wheless JW, Meng T, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters—a randomized, double-blind, placebo-controlled trial. Epilepsia. 2019;60:1797–808.CrossRefPubMedPubMedCentral

40.

Seinfeld S, Gelfand MA, Heller AH, Buan C, Slatko G. Safety and tolerability associated with chronic intermittent use of diazepam buccal film in adult, adolescent, and pediatric patients with epilepsy. Auton Autacoid Pharmacol. 2020;61:2426–34.CrossRef

41.

Rogawski MA, Heller AH. Diazepam buccal film for the treatment of acute seizures. Epilepsy Behav. 2019;101(Pt B):106537. https://doi.org/10.1016/j.yebeh.2019.106537.

42.

French JA, Wechsler R, Gelfand MA, Pollard JR, Vazquez B, Friedman D, et al. Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants. Epilepsia. 2019;60:1602–9.CrossRefPubMed

Title: Seizure Rescue Therapies: Comparing Approved and Commonly Used Benzodiazepine Formulations
Authors: Gregory L. Krauss
Reena Elizebath
Naluca Mwendaweli
Publication date: 01-04-2023
Publisher: Springer International Publishing
Keywords: Diazepam
Midazolam
Benzodiazepine
Clonazepam
Lorazepam
Published in: Neurotherapeutics / Issue 3/2023
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI: https://doi.org/10.1007/s13311-023-01359-3

Advances in Alzheimer's

Alzheimer's Disease
Independent Medical Education

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:

Lilly

Developed by: Springer Healthcare IME

Learn more

ERS Congress 2024

Springer Medicine

Seizure Rescue Therapies: Comparing Approved and Commonly Used Benzodiazepine Formulations

Abstract

Advances in Alzheimer's

ERS Congress 2024

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2023

Big Data in Stroke: How to Use Big Data to Make the Next Management Decision

Acute Treatment with the M-Channel (Kv7, KCNQ) Opener Retigabine Reduces the Long-Term Effects of Repetitive Blast Traumatic Brain Injuries

Combined Therapeutics: Future Opportunities for Co-therapy with Thrombectomy

Cell-Specific Expression of Human SIRT1 by Gene Therapy Reduces Retinal Ganglion Cell Loss Induced by Elevated Intraocular Pressure

BDNF Augmentation Using Riluzole Reverses Doxorubicin-Induced Decline in Cognitive Function and Neurogenesis

Correction to: Role of Estrogen-related Receptor γ and PGC-1α/SIRT3 Pathway in Early Brain Injury After Subarachnoid Hemorrhage

Advances in Alzheimer's